Skip to main content
main-content

18.08.2017 | CART and Immunotherapy (M Ruella, Section Editor) | Ausgabe 4/2017

Current Hematologic Malignancy Reports 4/2017

Novel Immunotherapies for Multiple Myeloma

Zeitschrift:
Current Hematologic Malignancy Reports > Ausgabe 4/2017
Autoren:
Mattia D’Agostino, Mario Boccadoro, Eric L. Smith
Wichtige Hinweise
This article was part of the Topical Collection on CART and Immunotherapy

Abstract

Purpose of Review

The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients’ survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies.

Recent Findings

Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants.

Summary

Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

Current Hematologic Malignancy Reports 4/2017Zur Ausgabe

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

Therapeutic Options for Aggressive T-Cell Lymphomas

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise